Partner
Bryan's litigation practice involves diverse technical areas, ranging from protecting the rights of innovative pharmaceutical companies in Abbreviated New Drug Application (ANDA) litigations to defending clients' right to use certain medical devices. He also has extensive experience in conducting IP due diligence investigations for all types of transactions.
Bryan served as managing partner of the firm's Brussels office for six years. During his tenure, he learned much about the European legal system, from the European Patent Convention (EPC) to the diversity of laws and practice among the European national systems. Strategic portfolio management and litigation counseling for European clients is also an important part of Bryan's practice. His knowledge of the European legal system and how it differs from that in the United States allows Bryan to counsel both European and domestic clients on a full range of IP issues and to find cohesive solutions tailored to the needs of companies with global interests.
Bryan lectures at various international programs and conferences targeted to U.S. and European business communities. He is fluent in French and has provided lectures in French on U.S. patent law topics involving litigation and due diligence reviews. He coauthored with other Finnegan lawyers a published course book on due diligence investigations and chemical patent law.
Bryan is recognized as a Life Sciences star by LMG Life Sciences in the fields of "Patent Strategy & Management" and "Hatch-Waxman Patent Litigation," and was selected as a "U.S. Intellectual Property Life Sciences Rising Star" at the fifth annual LMG Life Sciences awards dinner. The awards honor law firms and attorneys who have made a significant impact in the life sciences industry.
Intellectual Asset Management and The Legal 500 U.S. have each recognized Bryan in the areas of patent litigation and prosecution.
NOTE: No aspect of these rankings has been approved by the Supreme Court of New Jersey. Further information on methodologies is available via these links.
Valeant Pharmaceuticals NA, LLC v. Zydus Pharmaceuticals, Inc.
Represents Valeant in Hatch-Waxman patent infringement litigation concerning an ANDA for generic versions of Cardizem® LA.
3:17-cv-00449, D.N.J., Judges Sheridan, Goodman
Senju Pharmaceutical Co.; Bausch + Lomb v. Lupin Ltd.
Secured a permanent injunction against generic defendants on behalf of Senju and Bausch + Lomb in Hatch-Waxman patent infringement litigation concerning multiple ANDAs for generic versions of Prolensa®.
1:14-cv-00667, -04149; 1:15-cv-00335; 1:16-cv-01097, D.N.J., Judges Goodman, Shipp, Simandle, Williams
Secured a permanent injunction against generic defendants on behalf of Bausch + Lomb, Mitsubishi Tanabe, Ube, and Senju in Hatch-Waxman patent infringement litigation concerning multiple ANDAs for generic versions of opthalmic drug Bepreve®.
1:14-cv-01325, D.N.J., Judges Arpert, Hillman, Schneider, Shipp
Valeant Pharmaceuticals Int’l, Inc. v. Mylan Pharmaceuticals, Inc.
Represents Valeant, Salix, and Progenics in Hatch-Waxman patent infringement litigation concerning multiple ANDAs for generic subcutaneous versions of Relistor®. The District of New Jersey granted summary judgment in favor of Valeant, Salix and Progenics on U.S. Patent No. 8,552,025 covering Subcutaneous Relistor® through 2024.
2:15-cv-08180, 2:17-cv-06714, D.N.J., Judges Chesler, Waldor
Dow Pharmaceutical Sciences, Inc. v. Taro Pharmaceuticals U.S.A., Inc.
Represents Dow and Valeant in Hatch-Waxman patent infringement litigation concerning multiple ANDAs for generic versions of Onexton™.
2:16-cv-00217; 2:17-cv-00544, -01568, D.N.J., Judges Chesler, Waldor
Valeant Pharmaceuticals North America, LLC v. Actavis, Inc.
2:16-cv-04344, D.N.J., Judges Linares, Dickson
Articles
Strategies for Parameter Patents in the United States Strategies for Parameter Patents in the United States
February 1, 2023
Intellectual Property ManagementEvent
Navigating a Strategic Path Through Evolving US and EP Patent Landscapes Navigating a Strategic Path Through Evolving US and EP Patent Landscapes
November 8, 2022
Stockholm
Event
Fast Track to Allowance of Valuable Patent Claims Fast Track to Allowance of Valuable Patent Claims
September 14, 2022
Webinar
"Diner is a top performer in ANDA litigation and, similarly to Gramenopoulos, spent time in the Brussels office where he developed a robust understanding of European patent law."
Intellectual Asset Management Patent 1000
“… and Bryan Diner are straight shooters who truly litigate the merits of a case—if you have an issue, you can call them up and they'll address it in a matter-of-fact way.”
Intellectual Asset Management Patent 1000
“A former managing partner of the Brussels office, life sciences maven Bryan Diner is another prosecution ace with unparalleled knowledge of European patent law and abundant contentious experience.”
Intellectual Asset Management Patent 1000
“Other standout practitioners include…Bryan Diner, former managing partner of the Brussels office with an active litigation practice.”
Legal 500 United States
“'If it's a litigation matter, it would be Bryan Diner at Finnegan,' a peer says. 'Bryan understands patents with the eyes of both a patent practitioner and a litigator, and his knowledge of patent law is superior.'"
LMG Life Sciences
“Among the best strategic counsellors is…international pharmaceutical ace Bryan Diner.”
Intellectual Asset Management Patent 1000
“Diner’s combination of litigation and prosecution smarts and knowledge of the European patent system sets him apart…”
Intellectual Asset Management Patent 1000
“Jeffrey Berkowitz, Bryan Diner, Gerson Panitch and Anand Sharma all represent a class of litigators at Finnegan who benefit from well-rounded patent prosecution, counselling and licensing experience.”
Intellectual Asset Management Patent 1000
"Diner is a top performer in ANDA litigation and, similarly to Gramenopoulos, spent time in the Brussels office where he developed a robust understanding of European patent law."
Intellectual Asset Management Patent 1000
“… and Bryan Diner are straight shooters who truly litigate the merits of a case—if you have an issue, you can call them up and they'll address it in a matter-of-fact way.”
Intellectual Asset Management Patent 1000
“A former managing partner of the Brussels office, life sciences maven Bryan Diner is another prosecution ace with unparalleled knowledge of European patent law and abundant contentious experience.”
Intellectual Asset Management Patent 1000
“Other standout practitioners include…Bryan Diner, former managing partner of the Brussels office with an active litigation practice.”
Legal 500 United States
“'If it's a litigation matter, it would be Bryan Diner at Finnegan,' a peer says. 'Bryan understands patents with the eyes of both a patent practitioner and a litigator, and his knowledge of patent law is superior.'"
LMG Life Sciences
“Among the best strategic counsellors is…international pharmaceutical ace Bryan Diner.”
Intellectual Asset Management Patent 1000
“Diner’s combination of litigation and prosecution smarts and knowledge of the European patent system sets him apart…”
Intellectual Asset Management Patent 1000
“Jeffrey Berkowitz, Bryan Diner, Gerson Panitch and Anand Sharma all represent a class of litigators at Finnegan who benefit from well-rounded patent prosecution, counselling and licensing experience.”
Intellectual Asset Management Patent 1000
Award/Ranking
Five Finnegan Partners Named 2024 Leading Litigators in America by Lawdragon Five Finnegan Partners Named 2024 Leading Litigators in America by Lawdragon
October 30, 2023
The Lawdragon 500: Leading Litigators in AmericaAward/Ranking
Finnegan Upholds Tier 1 Marks in 2023 LMG Life Sciences Rankings Finnegan Upholds Tier 1 Marks in 2023 LMG Life Sciences Rankings
September 21, 2023
LMG Life SciencesPress Release
Managing Intellectual Property IP Stars: Finnegan Scores Top Patent Rankings Across the Board Managing Intellectual Property IP Stars: Finnegan Scores Top Patent Rankings Across the Board
July 13, 2023
Managing Intellectual PropertyPress Release
Finnegan Receives Top Rankings from Intellectual Asset Management; 46 Attorneys Ranked Finnegan Receives Top Rankings from Intellectual Asset Management; 46 Attorneys Ranked
June 30, 2023
Intellectual Asset ManagementPress Release
Finnegan Continues to Hold Top-Tier LMG Life Sciences 2022 Rankings Finnegan Continues to Hold Top-Tier LMG Life Sciences 2022 Rankings
September 22, 2022
LMG Life SciencesPress Release
45 Finnegan Attorneys Recommended by Intellectual Asset Management; Firm Continues to Be Top Ranked 45 Finnegan Attorneys Recommended by Intellectual Asset Management; Firm Continues to Be Top Ranked
July 8, 2022
Intellectual Asset ManagementDue to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.